Literature DB >> 21837605

Acute hemorrhagic colitis induced by the oral administration of oseltamivir used for influenza A treatment.

Y Nakagawa1, T Nagai, H Okawara, H Nakashima, A Hisamatsu, M Shuto, M Yamauchi, S Kai, S Yokoyama, K Murakami, T Fujioka.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21837605     DOI: 10.1055/s-0030-1256524

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


× No keyword cloud information.
  5 in total

1.  Case report on alimentary tract hemorrhage and liver injury after therapy with oseltamivir: A case report.

Authors:  Shengbo Fang; Lingli Qi; Na Zhou; Chunyan Li
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

2.  Laninamivir-induced ischemic enterocolitis: A case report.

Authors:  Chihiro Suzuki; Tsuneaki Kenzaka
Journal:  World J Clin Cases       Date:  2022-03-26       Impact factor: 1.337

3.  Comparison of the incidence of bleeding between baloxavir marboxil and other anti-influenza drugs among outpatients with influenza virus infection: A retrospective cohort study using an employment-based health insurance claims database in Japan.

Authors:  Azusa Hara; Kanae Hara; Takuji Komeda; Eriko Ogura; Shogo Miyazawa; Chiduru Kobayashi; Masakazu Fujiwara; Manami Yoshida; Hisashi Urushihara
Journal:  Pharmacoepidemiol Drug Saf       Date:  2021-12-23       Impact factor: 2.732

4.  An empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT™ is functionally superior to Freund's adjuvant.

Authors:  Natalie E Stevens; Cara K Fraser; Mohammed Alsharifi; Michael P Brown; Kerrilyn R Diener; John D Hayball
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

5.  Oseltamivir as a cause of acute enterorrhagia.

Authors:  Francisco Beraldi-Magalhães; Vera Batista; Marcelo Cordeiro-Santos
Journal:  Braz J Infect Dis       Date:  2016-08-16       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.